<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186729</url>
  </required_header>
  <id_info>
    <org_study_id>Version/date 180315</org_study_id>
    <nct_id>NCT03186729</nct_id>
  </id_info>
  <brief_title>Study of Antithrombotic Treatment After IntraCerebral Haemorrhage</brief_title>
  <acronym>STATICH</acronym>
  <official_title>Study of Antithrombotic Treatment After IntraCerebral Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effects of antithrombotic drugs (anticoagulant drugs or antiplatelet&#xD;
      drugs) for prevention of ischaemic events in patients With recent intracerebral haemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with spontaneous ICH have an increased risk of recurrent ICH and they also have an&#xD;
      increased risk of ischaemic diseases. Around 40-50% of patients use, or have an indication,&#xD;
      for antithrombotic drugs at the time of ICH. However, little is known about the benefits and&#xD;
      harms of using antithrombotic drugs for prevention of ischaemic events in patients who have&#xD;
      had an ICH.&#xD;
&#xD;
      There are only observational studies addressing this question. Because of the lack of&#xD;
      randomised-controlled trials and the inconclusive findings of the observational studies,&#xD;
      guidelines have variably endorsed both starting and avoiding antithrombotic drugs after ICH.&#xD;
&#xD;
      The investigators therefore want to study the effect and safety of using antithrombotic drugs&#xD;
      after ICH. Furthermore, since findings on MRI can be biomarkers for subsequent bleeding,&#xD;
      there will also be performed a sub-study of the association between such findings on MRI and&#xD;
      risk of recurrent ICH during treatment with antithrombotic drugs.&#xD;
&#xD;
      Patients with ICH during the last 6 months and with an indication for antithrombotic drugs&#xD;
      will be included. Patients with vascular disease and indication for antiplatelet drugs will&#xD;
      be randomised to antiplatelet treatment vs. no antithrombotic treatment. Patients with atrial&#xD;
      fibrillation and indication for anticoagulant treatment will be randomised to anticoagulant&#xD;
      treatment vs. no anticoagulant treatment. The follow up period is 2 years, and the primary&#xD;
      effect variable is new ICH. The investigators will also assess new intracranial haemorrhage,&#xD;
      extracranial haemorrhage and ischemic events, and functional and cognitive outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 2031</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised-controlled trial, parallel groups</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatal or non-fatal symptomatic ICH.</measure>
    <time_frame>2 years</time_frame>
    <description>Neurological deterioration or death associated with intracerebral haemorrhage found on CT scan, MRI, or autopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>2 years</time_frame>
    <description>Modified Rankin Scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>2 years</time_frame>
    <description>Death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular death</measure>
    <time_frame>2 years</time_frame>
    <description>Death of vascular cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic epidural, subdural, or subarachnoid haemorrhage</measure>
    <time_frame>2 years</time_frame>
    <description>Neurological deterioration or death associated with epidural, subdural, or subarachnoid haemorrhage found on CT scan, MRI, or autopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic major extracranial haemorrhage</measure>
    <time_frame>2 years</time_frame>
    <description>Clinically overt bleeding associated with one or more of:&#xD;
Transfusion of &gt;2 red cell units of blood&#xD;
A fall in haemoglobin of 2 g/dL, (1.24 mmol/L)&#xD;
Bleeding into retroperitoneum, intraocular space or major joint&#xD;
Bleeding leading to permanent treatment cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic events</measure>
    <time_frame>2 years</time_frame>
    <description>Transient ischaemic attack, ischaemic stroke, unstable angina, acute myocardial infarction (type 1), peripheral arterial occlusion, mesenteric ischaemia, retinal arterial occlusion, deep vein thrombosis or pulmonary embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive outcome at two years</measure>
    <time_frame>2 years</time_frame>
    <description>Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cerebral Hemorrhage</condition>
  <condition>Intracranial Hemorrhages</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Anticoagulant-Induced Bleeding</condition>
  <condition>Secondary Prevention</condition>
  <arm_group>
    <arm_group_label>Antithrombotic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antithrombotic treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombotic Agent</intervention_name>
    <description>Anticoagulant or antiplatelet drugs</description>
    <arm_group_label>Antithrombotic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age ≥18 years.&#xD;
&#xD;
          -  Spontaneous, primary ICH, of ≥1 day, but not more than 180 days after onset of&#xD;
             qualifying ICH, i.e.:&#xD;
&#xD;
               -  No preceding traumatic brain injury, based on history from the patient/witness of&#xD;
                  spontaneous symptom onset, and brain imaging appearances consistent of&#xD;
                  spontaneous ICH (i.e. any brain/bone/soft tissue appearances of trauma must have&#xD;
                  occurred secondary to a spontaneous ICH)&#xD;
&#xD;
               -  No 'secondary' or underlying structural cause (e.g. haemorrhagic transformation&#xD;
                  of an ischaemic stroke, aneurysm, tumour, arteriovenous malformation, or&#xD;
                  intracerebral venous thrombosis)&#xD;
&#xD;
          -  Patient have indication for antithrombotic (i.e. anticoagulant or antiplatelet) drug&#xD;
             for the prevention of ischaemic events, either antiplatelet drugs (for patients with&#xD;
             vascular disease), or anticoagulant drug for patients with atrial fibrillation.&#xD;
&#xD;
          -  Consent to randomisation from the patient (or personal / legal / professional&#xD;
             representative if the patient does not have mental capacity).&#xD;
&#xD;
          -  MRI (or CT) is performed before randomisation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clear indication for antiplatelet or anticoagulant treatment (e.g. prosthetic heart&#xD;
             valves).&#xD;
&#xD;
          -  Contraindications to the antithrombotic drug that will be administered.&#xD;
&#xD;
          -  Patient is pregnant, breastfeeding, or of childbearing age and not taking&#xD;
             contraception.&#xD;
&#xD;
          -  For patients examined with MRI: Contraindication for brain MRI&#xD;
&#xD;
          -  Malignancy with life expectancy less than 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torgeir Bruun Wyller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torgeir Bruun Wyller, PhD</last_name>
    <phone>004791166682</phone>
    <email>t.b.wyller@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Rostrup Kruuse, PhD</last_name>
      <email>christina.kruuse@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Larsen, MD</last_name>
      <phone>004798671138</phone>
      <email>k.t.larsen@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Ole Morten Rønning, PhD</last_name>
      <phone>004745601774</phone>
      <email>o.m.ronning@medisin.uio.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>SE-90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva-Lotta Glader, PhD</last_name>
      <email>eva-lotta.glader@umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Johanna Pennlert, PhD</last_name>
      <email>johanna.pennlert@umu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Torgeir Bruun Wyller</investigator_full_name>
    <investigator_title>Project leader</investigator_title>
  </responsible_party>
  <keyword>Intracerebral hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared within the COCROACH Collaboration.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

